A Randomized Phase 3 Trial of IMA203 PRAME-directed TCR T-cell Therapy vs Investigator’s Choice in Unresectable or Metastatic Melanoma post ICI (IMA203-301) (SUPRAME)

Principal Investigator

Dr Miranda Payne

Contact us

Email: latephaseoncology@ouh.nhs.uk

IRAS number

1012574